Serum netrin-1 levels in systemic sclerosis patients with capillary abnormalities

[1]  N. Kaminski,et al.  Macrophage-derived netrin-1 drives adrenergic nerve-associated lung fibrosis. , 2021, The Journal of clinical investigation.

[2]  Xu Zhang,et al.  Gastric cancer-derived mesenchymal stromal cells trigger M2 macrophage polarization that promotes metastasis and EMT in gastric cancer , 2019, Cell Death & Disease.

[3]  R. Giacomelli,et al.  Macrophages with regulatory functions, a possible new therapeutic perspective in autoimmune diseases. , 2019, Autoimmunity reviews.

[4]  Maurizio Cutolo,et al.  Pathophysiology of systemic sclerosis: current understanding and new insights , 2019, Expert review of clinical immunology.

[5]  A. M. El-Sayed,et al.  Progressive systemic sclerosis in Egyptian patients: Clinical characteristics and nail fold capillaroscopy , 2018, The Egyptian Rheumatologist.

[6]  A. Kalergis,et al.  Implications of macrophage polarization in autoimmunity , 2018, Immunology.

[7]  Peng Chen,et al.  Netrin-1 promotes diabetic corneal wound healing through molecular mechanisms mediated via the adenosine 2B receptor , 2018, Scientific Reports.

[8]  J. Gutermuth,et al.  The role of endothelial cells in the vasculopathy of systemic sclerosis: A systematic review. , 2017, Autoimmunity reviews.

[9]  M. Nazarinia,et al.  Serum vascular endothelial growth factor (VEGF), soluble VEGF receptor-1 (sVEGFR-1) and sVEGFR-2 in systemic sclerosis patients: Relation to clinical manifestations and capillaroscopy findings , 2017 .

[10]  K. Moore,et al.  Netrin‐1 and its receptor Unc5b are novel targets for the treatment of inflammatory arthritis , 2016, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  L. Niklason,et al.  Netrin‐1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin‐Induced Pulmonary Fibrosis , 2016, Arthritis & rheumatology.

[12]  J. Ma,et al.  Netrin-1 promotes mesenchymal stem cell revascularization of limb ischaemia , 2016, Diabetes & vascular disease research.

[13]  K. Moore,et al.  Netrin‐1 Is a Critical Autocrine/Paracrine Factor for Osteoclast Differentiation , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  Zui Tan,et al.  Netrin-1 with stem cells promote angiogenesis in limb ischemic rats. , 2014, The Journal of surgical research.

[15]  M. Mayes,et al.  An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative , 2013 .

[16]  G. Ramesh,et al.  Netrin-1-treated macrophages protect the kidney against ischemia-reperfusion injury and suppress inflammation by inducing M2 polarization. , 2013, American journal of physiology. Renal physiology.

[17]  V. Ganapathy,et al.  Kidney proximal tubular epithelial-specific overexpression of netrin-1 suppresses inflammation and albuminuria through suppression of COX-2-mediated PGE2 production in streptozotocin-induced diabetic mice. , 2012, The American journal of pathology.

[18]  K. Moore,et al.  The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting macrophage emigration from plaques , 2011, Nature Immunology.

[19]  Maurizio Cutolo,et al.  Assessing microvascular changes in systemic sclerosis diagnosis and management , 2010, Nature Reviews Rheumatology.

[20]  R. Christmann,et al.  The cytokine language of monocytes and macrophages in systemic sclerosis , 2010, Arthritis Research & Therapy.

[21]  R. Faull,et al.  Characterization of the Netrin/RGMa receptor neogenin in neurogenic regions of the mouse and human adult forebrain , 2010, The Journal of comparative neurology.

[22]  P. Mehlen,et al.  Netrin-1 and its dependence receptors as original targets for cancer therapy , 2010, Current opinion in oncology.

[23]  V. Laudet,et al.  Inhibition of endothelial cell apoptosis by netrin-1 during angiogenesis. , 2009, Developmental cell.

[24]  D. Cappellen,et al.  Netrin-1 acts as a survival factor for aggressive neuroblastoma , 2009, The Journal of experimental medicine.

[25]  E. Brambilla,et al.  Interference with netrin-1 and tumor cell death in non-small cell lung cancer. , 2009, Journal of the National Cancer Institute.

[26]  T. Wu,et al.  Netrin-1 attenuates ischemic stroke-induced apoptosis , 2008, Neuroscience.

[27]  I. Treilleux,et al.  Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer , 2008, Proceedings of the National Academy of Sciences.

[28]  Joshua D. Wythe,et al.  The netrin receptor UNC5B promotes angiogenesis in specific vascular beds , 2008, Development.

[29]  B. Kahaleh.  Vascular disease in scleroderma: mechanisms of vascular injury. , 2008, Rheumatic diseases clinics of North America.

[30]  Christian Fischer,et al.  Activation of the UNC5B receptor by Netrin-1 inhibits sprouting angiogenesis. , 2007, Genes & development.

[31]  Chi-Bin Chien,et al.  Netrins Promote Developmental and Therapeutic Angiogenesis , 2006, Science.

[32]  Hua “Linda” Cai,et al.  Netrin‐1 induces angiogenesis via a DCC dependent ERK1/2‐eNOS feed‐forward mechanism , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Fujimoto,et al.  Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis. , 2005, Journal of dermatological science.

[34]  Dean Y. Li,et al.  The axonal attractant Netrin-1 is an angiogenic factor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Li Yuan,et al.  The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system , 2004, Nature.

[36]  Till Acker,et al.  Uncontrolled Expression of Vascular Endothelial Growth Factor and Its Receptors Leads to Insufficient Skin Angiogenesis in Patients With Systemic Sclerosis , 2004, Circulation research.

[37]  Richard W. Martin,et al.  Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. , 1995, The Journal of rheumatology.

[38]  T. Medsger,et al.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.